{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:47:17Z","timestamp":1793908037191,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ahj.2026.107546","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:36:09Z","timestamp":1786116969000},"page":"107546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["HPS-4\/TIMI 65\/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics"],"prefix":"10.1016","volume":"303","author":[{"given":"Marion M.","family":"Mafham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-983X","authenticated-orcid":false,"given":"Mohammed G.","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno R.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Goonasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma C.","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Landray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Lay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Lesogor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Nunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Rizkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Wallendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Wijesurendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wincott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107546_bib0001","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107546_bib0002","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107546_bib0003","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107546_bib0004","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0005","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0006","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0007","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in Patients without a Previous Myocardial Infarction or Stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0008","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ahj.2026.107546_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001632","article-title":"PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites","volume":"10","author":"Kent","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ahj.2026.107546_bib0011","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2026.107546_bib0012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.ahj.2026.107546_bib0013","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0014","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107546_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0016","first-page":"177","article-title":"Advancing monoclonal antibody manufacturing: process optimization, cost reduction strategies, and emerging technologies","volume":"19","author":"Ranbhor","year":"2025","journal-title":"Biologics"},{"key":"10.1016\/j.ahj.2026.107546_bib0017","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jcph.2045","article-title":"Inclisiran: a novel small interfering RNA drug for low-density lipoprotein reduction","volume":"62","author":"Smith","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ahj.2026.107546_bib0018","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0019","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An ``Inclisiran First'' strategy vs usual care in patients with atherosclerotic cardiovascular disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107546_bib0020","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1093\/eurheartj\/ehaf685","article-title":"Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial","volume":"47","author":"Landmesser","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107546_bib0021","unstructured":"ORION-4 ClinicalTrials.gov record, https:\/\/clinicaltrials.gov\/study\/NCT03705234, 2025. Accessed Januaury 25, 2026."},{"key":"10.1016\/j.ahj.2026.107546_bib0022","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ahj.2026.107546_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107546_bib0024","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107546_bib0025","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ahj.2026.107546_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/j.ahj.2026.107546_bib0027","unstructured":"International Conference on Harmonisation (ICH) Expert Working Group. ICH harmonised tripartite guideline: statistical principles for clinical trials (E9), 1998 https:\/\/database.ich.org\/sites\/default\/files\/E9_Guideline.pdf. Accessed January 20, 2026."},{"key":"10.1016\/j.ahj.2026.107546_bib0028","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Progr Cardiovasc Dis"},{"key":"10.1016\/j.ahj.2026.107546_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ahj.2026.107546_bib0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326002085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326002085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:36:48Z","timestamp":1793281008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326002085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":30,"alternative-id":["S0002870326002085"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107546","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPS-4\/TIMI 65\/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107546"}}